GRTX

Galera Therapeutics, Inc. (GRTX) | Rumor.io

Galera Therapeutics

GRTX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)100%

Price to earnings ratio0.14

Market capitalization6.8M

Earnings per share0.64

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about GRTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Apr 19

Galera Therapeutics, Inc. (GRTX) stock is not mentioned in the provided social media posts.
The posts primarily discuss a Mortal Kombat core installation on the Mister Fpga and its availability through Patreon.
The conversation is off-topic, with users discussing unrelated topics such as a NEO GEO console and a SNK console.

Generated by AI

Sentiment

Of the messages about GRTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	75% +2.52
Bearish	—	—	—	25% -2.52

Bullish· Apr 17

The market is expected to see an explosion in $GRTX any minute now, potentially leading to a significant price increase.
There is a massive bid coming in for $GRTX, with over 1.2 million shares being bought at $0.2150, which may be short covering or a strategic move to prop up the stock.
$GRTX is expected to break through key resistance levels, with a price target of $0.16-$0.17 cents predicted for the next day.

Bearish· Apr 17

$GRTX has a high debt burden of $157M, which may lead to bankruptcy.
The company has faced significant challenges, including FDA rejections of its drugs, a failed trial, and a net loss of over $60M last year.
$GRTX's bid orders are likely fake, with a large short position trying to cover, and the stock is expected to drop 15-25% by tomorrow's premarket.

Generated by AI

Topics

Of the messages about GRTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	0%	0.67%
Announcements	—	—	100%	99.33%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	0%

Analysts· Dec 20

Citigroup raised the price target on Galera Therapeutics (GRTX) to $20, implying 575% upside.
The analyst gave GRTX's treatment a 90% chance of success based on new data.
Institutional ownership of GRTX is 66.65%, and the stock has a small float of 10.53 million shares.

Announcements· Aug 10

Galera Therapeutics' balance of cash, cash equivalents, and marketable securities as of June 30, 2023 was approximately $38.8 million.
The FDA has granted orphan drug designation to Galera's second product candidate, rucosopasem manganese, for the treatment of pancreatic cancer.
The FDA declined to approve Galera's inflammation disease drug, causing a significant decline in the company's shares by 81.7% before the announcement.

Technical Analysis· Dec 28

$GRTX has shown strong upward momentum since mid-December after announcing the correction of an error in their cancer therapy results.
The stock has a big gap up still to fill and is experiencing volatile daily volume, making it primed for intraday trading or a slightly longer hold.
The RSI for $GRTX is currently oversold, with a daily RSI below 70 and other time frames showing similar readings, indicating a potential reversal and next leg up.

Generated by AI

Community

Of the messages about GRTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	77.78%	3.21%
Newcomers	—	—	22.22%	96.79%

Regulars· Aug 10

Don't take unknown risks, including FDA decisions, and keep a cash reserve, as the process of drug development is a black box.
Be cautious of FDA CRLs, as they can lead to significant losses, and consider the company's cash position and debt.
A potential bottom is identified, with a short-term higher low, and a recommendation to trail stops below prior lows.

Newcomers· Aug 10

Newcomers to the GRTX discussion are noting that biotech stocks can be particularly vulnerable to negative FDA rulings or bankruptcy filings, citing examples of companies that have been heavily impacted.
Some newcomers are focusing on the cash reserves of GRTX, noting that the company has $38.8M in cash and that the stock is worth at least $1.09 based on this alone.
Others are warning that GRTX's recent data may be a red flag, particularly if it is compared to earlier data, and that this could impact the company's chances of meeting its PDUFA deadline.

Generated by AI

News

Galera Therapeutics Announces Material Changes to Security Holder Rights

Detailed price information for Galera Therapeutics Inc (GRTX) from The Globe and Mail including charting and trades.

2mo agoThe Globe and Mail

Also Discussed

Investors talking about GRTX also mention

#	Name	Attention
1	Biofrontera Inc.BFRI	0%0
2	Longeveron Inc. Class A Common StockLGVN	0%0
3	PTPI - Petros Pharmaceuticals, Inc.	——
4	Society Pass IncorporatedSOPA	0%0
5	Nutriband Inc.NTRB	0%0
6	Ensysce Biosciences, Inc. Common StockENSC	0%0
7	SGMA - SigmaTron International, Inc.	——
8	Context Therapeutics Inc.CNTX	0%0
9	Pasithea Therapeutics Corp.KTTA	0%0
10	GRCL - Gracell Biotechnologies Inc.	——